Abstract
Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.
Keywords: Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism
Anti-Cancer Agents in Medicinal Chemistry
Title: Brutons Tyrosine Kinase as a New Therapeutic Target
Volume: 7 Issue: 6
Author(s): Fatih M. Uckun, Heather E. Tibbles and Alexei O. Vassilev
Affiliation:
Keywords: Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism
Abstract: Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.
Export Options
About this article
Cite this article as:
Uckun M. Fatih, Tibbles E. Heather and Vassilev O. Alexei, Brutons Tyrosine Kinase as a New Therapeutic Target, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/187152007784111331
DOI https://dx.doi.org/10.2174/187152007784111331 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Validated Enantioselective HPLC Method for Assay of S-Amlodipine Using Crown Ether as a Chiral Stationary Phase
Current Analytical Chemistry The Multifunctional Protein C System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Lipoxygenase: An Emerging Target for Stroke Therapy
CNS & Neurological Disorders - Drug Targets Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Oxidized Phospholipids in Acute Lung Injury
Current Respiratory Medicine Reviews Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Cardiovascular & Hematological Disorders-Drug Targets Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology